| Code | Definition |
| 001 |
Patient seeks protection |
| 002 |
Undergoing elective splenectomy |
| 003 |
Immunocompromised |
| 004 |
Recipient of a hematopoietic stem cell transplant |
| 005 |
Hepatitis C virus infection |
| 006 |
Receives clotting factor concentrates |
| 007 |
Pregnant |
| 008 |
Travel to an area of active cholera transmission |
| 009 |
Breastfeeding |
| 010 |
Cerebrospinal fluid leaks |
| 011 |
Cochlear implants |
| 012 |
Family history of altered immunocompetence |
| 013 |
Severe Combined Immunodeficiency [SCID] |
| 014 |
Diabetes |
| 015 |
Chronic liver disease |
| 016 |
Chronic heart disease |
| 017 |
Chronic lung disease |
| 018 |
Laboratory Evidence of Immunity or confirmation of Hepatitis A disease |
| 019 |
Laboratory Evidence of Immunity or confirmation of Hepatitis B disease |
| 020 |
Laboratory Evidence of Immunity for Measles |
| 021 |
Laboratory Evidence of Immunity for Mumps |
| 022 |
Laboratory Evidence of Immunity for Rubella |
| 023 |
Laboratory Evidence of Immunity or confirmation of Varicella disease |
| 024 |
Healthcare provider verified history of or diagnosis of Varicella |
| 025 |
Healthcare provider verified history or diagnosis of Herpes Zoster |
| 026 |
Persons with perinatal HIV infection who do not have evidence of severe immunosuppression and who were vaccinated with MMR before establishment of antiviral therapy [ART] |
| 027 |
Asthma |
| 028 |
Intussusception |
| 029 |
Acute gastroenteritis |
| 030 |
Acute febrile illness |
| 031 |
Tuberculosis |
| 032 |
Dialysis patient |
| 033 |
Taken influenza antiviral medications within the previous 48 hours |
| 034 |
Receiving long-term aspirin therapy |
| 035 |
Antimicrobial or antimalarial taken within 72 hours |
| 036 |
Men who have sex with men |
| 037 |
Not in a long-term, mutually monogamous relationship |
| 038 |
Sex partner of Hepatitis B surface antigen-positive persons |
| 039 |
Receives treatment for STD |
| 040 |
Illicit drug use |
| 041 |
Illicit injection drug use |
| 042 |
Smoke cigarettes |
| 043 |
Alcoholism |
| 044 |
Anticipate close personal contact with international adoptee |
| 045 |
Travel to country with a Yellow Fever vaccination entry requirement |
| 046 |
College students living in residence halls |
| 047 |
Resident of area at risk for exposure to the disease |
| 048 |
Travelling Internationally |
| 049 |
Working with Hepatitis A virus in research setting |
| 050 |
Microbiologists routinely exposed to Neisseria meningitidis |
| 051 |
Microbiology laboratorians who work frequently with S. typhi |
| 052 |
Laboratory personnel who might be exposed to YFV |
| 053 |
Rabies researchers |
| 054 |
Laboratory workers who handle specimens that might contain polioviruses |
| 055 |
Health care personnel |
| 056 |
Health-care workers who have close contact with patients who might be excreting wild polioviruses |
| 057 |
Public safety worker exposed to blood or infection body fluids |
| 058 |
Staff of institution for persons with developmental disabilities |
| 059 |
Occupational exposure for Hepatitis A |
| 060 |
Veterinarians and their staff |
| 061 |
Animal handlers |
| 062 |
Persons whose activities bring them into frequent contact with rabies virus or potentially rabid animals |
| 063 |
Post secondary student |
| 064 |
Military recruits |
| 065 |
Client of institution for persons with developmental disabilities |
| 066 |
Chronic renal failure |
| 068 |
In drug abuse treatment and prevention facility |
| 069 |
In correctional facility |
| 070 |
Persons at risk during an outbreak |
| 071 |
Household contact with hepatitis B surface antigen-positive persons |
| 072 |
Intimate exposure to a documented S. typhi carrier |
| 073 |
Household and close contacts of immunocompromised persons |
| 074 |
Negative serological screening for varicella |
| 075 |
Transgender person |
| 076 |
Progressive neurologic disorder |
| 077 |
Received inactivated or unknown measles vaccine between 1963-1967 |
| 078 |
Received killed or unknown Mumps vaccine before 1979 |
| 079 |
Encephalopathy not attributable to another identifiable cause within 7 days of administration of a previous dose of Tdap, DTP, or DTaP vaccine |
| 080 |
Adverse reaction to vaccine component |
| 081 |
Severe allergic reaction after previous dose of Polio |
| 082 |
Severe allergic reaction after previous dose of Japanese Encephalitis |
| 083 |
Severe allergic reaction after previous dose of Rotavirus |
| 084 |
Severe allergic reaction after previous dose of Typhoid |
| 085 |
Severe allergic reaction after previous dose of Influenza |
| 086 |
Severe allergic reaction after previous dose of Pertussis |
| 087 |
Severe allergic reaction after previous dose of Diphtheria |
| 088 |
Severe allergic reaction after previous dose of Tetanus |
| 089 |
Severe allergic reaction after previous dose of Varicella |
| 090 |
Severe allergic reaction after previous dose of HPV |
| 091 |
Severe allergic reaction after previous dose of Measles |
| 092 |
Severe allergic reaction after previous dose of Mumps |
| 093 |
Severe allergic reaction after previous dose of Rubella |
| 094 |
Severe allergic reaction after previous dose of Pneumococcal |
| 095 |
Severe allergic reaction after previous dose of Meningococcal |
| 096 |
Severe allergic reaction after previous dose of Hepatitis A |
| 097 |
Severe allergic reaction after previous dose of Hepatitis B |
| 098 |
Severe allergic reaction after previous dose of Hib |
| 099 |
Severe allergic reaction after previous dose of Yellow Fever |
| 100 |
Severe allergic reaction after previous dose of live zoster |
| 101 |
Allergic reaction to egg protein |
| 102 |
Severe allergic reaction to gelatin |
| 103 |
Severe allergic reaction to arginine |
| 104 |
Allergic reaction to latex |
| 105 |
Severe allergic reaction to chicken protein |
| 106 |
Severe allergic reaction to gentamicin |
| 107 |
Severe allergic reaction to neomycin |
| 108 |
Severe allergic reaction to streptomycin |
| 109 |
Severe allergic reaction to polymyxin B |
| 110 |
Hypersensitivity to yeast |
| 111 |
Hypersensitivity to the preservative 2-phenoxyethanol |
| 112 |
Hypersensitivity to alum |
| 113 |
Severe allergic reaction after previous dose of Rabies |
| 114 |
End stage renal disease |
| 115 |
Severe allergic reaction to protamine sulfate |
| 116 |
Severe allergic reaction after previous dose of Meningococcal B |
| 117 |
Severe allergic reaction to diphtheria toxoid |
| 118 |
Severe allergic reaction to tetanus toxoid |
| 119 |
Severe allergic reaction after previous dose of cholera |
| 120 |
Begin Date of antiviral therapy [ART] |
| 121 |
Homelessness |
| 122 |
Severe allergic reaction after previous dose of COVID-19 |
| 123 |
Severe allergic reaction after previous dose of Ebola |
| 124 |
Severe allergic reaction to rice protein |
| 125 |
Tetanus IG administration |
| 126 |
Hep A IG administration |
| 127 |
Hep B IG administration |
| 128 |
Rabies IG administration |
| 129 |
Varicella IG administration |
| 130 |
Measles prophylaxis IG administration - Standard |
| 131 |
Measles prophylaxis IG administration - Immunocompromised Contact |
| 132 |
RBC [adenine-saline added] blood transfusion |
| 133 |
Packed RBC blood transfusion |
| 134 |
Whole blood transfusion |
| 135 |
Plasma/platelet products blood transfusion |
| 136 |
Cytomegalovirus IGIV |
| 137 |
IGIV - Replacement therapy for immune deficiencies |
| 138 |
IGIV - Immune thrombocytopenic purpura treatment |
| 139 |
IGIV - Postexposure varicella prophylaxis |
| 140 |
IGIV - Immune thrombocytopenic purpura treatment |
| 141 |
IGIV - Kawasaki disease |
| 142 |
Travel to or working in countries that have high or intermediate endemicity of Hepatitis A |
| 143 |
Travel to areas or countries where polio is epidemic or endemic |
| 144 |
International travel with possible contact with animals in areas where rabies is enzootic and immediate access to appropriate medical care might be limited |
| 145 |
B-lymphocyte [humoral] - Severe antibody deficiencies |
| 146 |
B-lymphocyte [humoral] - Less severe antibody deficiencies |
| 147 |
T-lymphocyte [cell-mediated and humoral] - Complete defects |
| 148 |
T-lymphocyte [cell-mediated and humoral] - Partial defects |
| 149 |
T-lymphocyte [cell-mediated and humoral] - interferon-gamma/Interleukin 12 axis deficiencies |
| 150 |
T-lymphocyte [cell-mediated and humoral] - interferon-gamma or interferon-alpha |
| 151 |
Persistent complement, properdin, or factor B deficiency |
| 152 |
Phagocytic function - Chronic granulomatous disease |
| 153 |
Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency |
| 154 |
HIV/AIDS - severely immunocompromised |
| 155 |
HIV/AIDS - not severely immunocompromised |
| 156 |
Generalized malignant neoplasm |
| 157 |
Transplantation |
| 158 |
Immunosuppressive therapy |
| 159 |
Radiation therapy |
| 160 |
Anatomical or functional asplenia |
| 161 |
Chronic kidney disease |
| 162 |
Travel to areas at risk for Yellow Fever transmission |
| 163 |
Travel to areas in which there is a recognized risk of exposure to S. typhi |
| 164 |
Travel to or are residents of countries in which meningococcal disease is hyperendemic or epidemic |
| 165 |
Longer-term (e.g., 1 month or more) travel to a JE-endemic area |
| 166 |
Travel to countries with high or intermediate prevalence of chronic HBV infection |
| 167 |
Nephrotic Syndrome |
| 168 |
Chemotherapy |
| 169 |
History of sexual abuse or assault |
| 170 |
Onset of pregnancy |
| 171 |
Date of hematopoietic stem cell transplant |
| 172 |
Severe allergic reaction after previous dose of recombinant zoster |
| 173 |
Moving to JE-endemic country to take up residence |
| 174 |
Frequent travel to JE-endemic areas |
| 175 |
Patient seeks Hepatitis A protection |
| 176 |
Patient seeks Hepatitis B protection |
| 177 |
Patient seeks Meningococcal B protection |
| 178 |
Leukemia |
| 179 |
Lymphoma |
| 180 |
Hodgkin's disease |
| 181 |
Multiple myeloma |
| 182 |
Ebola virus outbreak response |
| 183 |
Health care personnel at federally designated Ebola treatment center in U.S. |
| 184 |
Laboratorians or other staff at biosafety level 4 facilities in U.S. |
| 185 |
Persons in settings that provide services to adults with high proportion of those persons have risk factors for HAV infection |
| 186 |
HIV Infection |
| 187 |
Allergic reaction to polysorbate 80 |
| 188 |
Known allergy to Polyethylene glycol [PEG] |
| 189 |
Active treatment for solid tumors |
| 190 |
Active treatment for hematologic malignancies |
| 191 |
Receipt of CAR-T-cell therapy |
| 192 |
Severe allergic reaction after previous dose of any egg-based IIV or LAIV influenza vaccine |
| 193 |
Severe allergic reaction after previous dose of any ccIIV influenza vaccine |
| 194 |
Severe allergic reaction after previous dose of any RIV influenza vaccine |
| 195 |
Occupations at increased risk for COVID-19 exposure and transmission |
| 196 |
Residing in an institutional setting at increased risk for COVID-19 exposure and transmission |
| 197 |
Resident of a long term care facility |
| 198 |
Cancer |
| 199 |
Interstitial lung disease |
| 200 |
Cystic fibrosis |
| 201 |
Pulmonary hypertension |
| 202 |
Dementia |
| 203 |
Down syndrome |
| 204 |
Obesity |
| 205 |
Thalassemia |
| 206 |
Cerebrovascular disease |
| 207 |
Substance use disorder |
| 208 |
Mental Health conditions |
| 209 |
History of thrombosis with thrombocytopenia following the Janssen COVID-19 Vaccine or any other adenovirus-vectored COVID-19 vaccines |
| 210 |
Severe allergic reaction after previous dose of Dengue vaccine |
| 211 |
Evidence of previous dengue infection and living in areas where dengue is endemic |
| 212 |
Health care personnel involved in the care and transport of patients with suspected or confirmed Ebola virus disease at Special Pathogen Treatment Centers |
| 213 |
Laboratorians and support staff members at Laboratory Response Network (LRN) facilities that handle specimens that might contain replication-competent Ebola virus in the United States |
| 214 |
Chronic obstructive pulmonary disease |
| 215 |
Emphysema |
| 216 |
Iatrogenic Immunosuppression |
| 217 |
Persons working in rabies vaccine production facilities |
| 218 |
Persons performing testing for rabies in diagnostic laboratories |
| 219 |
Persons who frequently handle bats |
| 220 |
Persons who frequently have contact with bats |
| 221 |
Persons who frequently enter high-density bat environments |
| 222 |
Persons who frequently perform animal necropsies |
| 223 |
Severe allergic reaction after previous dose of orthopoxvirus vaccine |
| 224 |
History or presence of atopic dermatitis |
| 225 |
Household contact with history or presence of atopic dermatitis |
| 226 |
Active exfoliative skin conditions |
| 227 |
Household contact with active exfoliative skin conditions |
| 228 |
Household contact is pregnant |
| 229 |
Age is less than 1 year |
| 230 |
Household contact who is less than 1 year of age |
| 231 |
3 or more known major cardiac risk factors |
| 232 |
Research laboratory personnel working with more virulent orthopoxviruses (e.g., Variola virus or mpox virus) |
| 233 |
Clinical laboratory personnel performing diagnostic testing for more virulent orthopoxviruses (e.g., Variola virus or mpox virus) |
| 234 |
Designated response team members working with more virulent orthopoxviruses (e.g., Variola virus or mpox virus) |
| 235 |
Healthcare personnel who care for patients infected with more virulent orthopoxviruses (e.g., Variola virus or mpox virus) |
| 236 |
Research laboratory personnel working with less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus) |
| 237 |
Clinical laboratory personnel performing diagnostic testing for less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus) |
| 238 |
Designated response team members working with less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus) |
| 239 |
Healthcare personnel who administer ACAM2000 |
| 240 |
Healthcare personnel who care for patients infected with less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus) |
| 241 |
Known exposure to mpox |
| 242 |
Presumed exposure to mpox |
| 243 |
Lack of laboratory confirmation of a previous Dengue infection |
| 244 |
Severe allergic reaction after previous dose of RSV vaccine |
| 245 |
American Indian or Alaskan Native |
| 246 |
Severe immunocompromise |
| 247 |
Gay, bisexual, and other men who have sex with men, transgender or nonbinary peope who in the past 6 months have had one of the following: 1) A new diagnosis of ≥ 1 sexually transmitted disease 2) More than one sex partner 3) Sex at a commercial sex venue 4) Sex in association with a large public event in a geographic area where mpox transmission is occurring |
| 248 |
Sexual partners of gay, bisexual, and other men who have sex with men, transgender or nonbinary peope who in the past 6 months have had one of the following: 1) A new diagnosis of ≥ 1 sexually transmitted disease 2) More than one sex partner 3) Sex at a commercial sex venue 4) Sex in association with a large public event in a geographic area where mpox transmission is occurring |
| 249 |
Moving or traveling to an area where TBE is endemic and will have extensive exposure to ticks because of their planned outdoor activities and itinerary |
| 250 |
Moving or traveling to an area where TBE is endemic who might engage in outdoor activities in areas where ticks are likely to be found |
| 251 |
Laboratory workers with a potential for exposure to TBE virus |
| 252 |
Severe allergic reaction after previous dose of Tick-borne Encephalitis vaccine |